会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • Anti-annexin-V monoclonal antibodies, and preparation and use thereof
    • 抗 - 膜联蛋白-V单克隆抗体及其制备和应用
    • US5767247A
    • 1998-06-16
    • US669509
    • 1996-10-22
    • Noboru KanekoRyuko MatsudaTadahiro KajitaYohsuke Ohta
    • Noboru KanekoRyuko MatsudaTadahiro KajitaYohsuke Ohta
    • C07K16/18C12N15/06C12P21/08C07K16/28G01N33/53
    • C07K16/18G01N2333/4718
    • Using human annexin-V or human annexin-V plus dog annexin-V as antigen(s), hybridoma cell lines are prepared which are capable of producing anti-annexin-V monoclonal antibodies having a binding specificity to antigenic determinant site on annexin-V as antigenic protein and belonging to immunoglobulin G class. By the hybridoma cell lines are produced the anti-annexin-V monoclonal antibodies, with which a diagnostic agent is provided for diagnosis of myocardial infarction and angina pectoris. There is also provided diagnosis of myocardial infarction and angina pectoris using a first and a second monoclonal antibodies produced by the hybridoma cell lines to quantitate human annexin-V in a sample, in which an antigen-antibody reaction on annexin-V in the sample is caused with the first anti-annexin-V monoclonal antibody to form an annexin-V antigen/anti-annexin-V monoclonal antibody complex, the antigenic site of annexin-V of the formed annexin-V antigen/annexin-V monoclonal antibody complex is allowed to be bound with a labeled anti-annexin-V polyclonal or second monoclonal antibody so as to form a labeled form of said annexin-V antigen/anti-annexin-V monoclonal antibody complex bound with the polyclonal or the second monoclonal antibody, and the labeled form of the complex is quantitatively analyzed.
    • PCT No.PCT / JP95 / 02305 Sec。 371日期1996年10月22日第 102(e)日期1996年10月22日PCT 1995年11月10日PCT PCT。 出版物WO96 / 15152 日期1996年5月23日使用人膜联蛋白-V或人膜联蛋白-V加狗膜联蛋白-V作为抗原,制备能够产生对抗原决定簇位点具有结合特异性的抗叶绿体-V单克隆抗体的杂交瘤细胞系 对膜联蛋白-V作为抗原蛋白,属于免疫球蛋白G类。 通过杂交瘤细胞系产生抗膜联蛋白-V单克隆抗体,通过该单克隆抗体提供用于诊断心肌梗塞和心绞痛的诊断剂。 还提供使用由杂交瘤细胞系产生的第一和第二单克隆抗体来定量样品中的人膜联蛋白-V的心肌梗塞和心绞痛的诊断,其中样品中对膜联蛋白-V的抗原 - 抗体反应是 由第一抗膜联蛋白-V单克隆抗体形成膜联蛋白-V抗原/抗 - 膜联蛋白-V单克隆抗体复合物,形成的膜联蛋白-V抗原/膜联蛋白-V单克隆抗体复合物的膜联蛋白-V的抗原位点是 允许与标记的抗 - 膜联蛋白-V多克隆或第二单克隆抗体结合,以形成与多克隆或第二单克隆抗体结合的所述膜联蛋白-V抗原/抗 - 膜联蛋白-V单克隆抗体复合物的标记形式,以及 定量分析复合物的标记形式。
    • 5. 发明授权
    • Anti-HBs monoclonal antibody
    • 抗HBs单克隆抗体
    • US07871621B2
    • 2011-01-18
    • US11435835
    • 2006-05-18
    • Kazuhiko TakedaTadahiro KajitaAyumi Asaeda
    • Kazuhiko TakedaTadahiro KajitaAyumi Asaeda
    • A61K39/42C07K16/00
    • G01N33/576C07K16/082G01N2333/02
    • An anti-HBs monoclonal antibody is described herein. This antibody can bind to the following: (i) a wild type HBsAg; (ii) at least one mutant HBsAg selected from the group consisting of a first mutant HBsAg and a second mutant HBsAg; and (iii) at least one mutant HBsAg selected from the group consisting of a third mutant HBsAg and a fourth mutant HBsAg. The first mutant HBsAg has a mutation at position 120. The second mutant HBsAg has a mutation at position 141. The third mutant HBsAg has a substitution to a lysine at position 118. The fourth mutant HBsAg has only one mutation at position 144 and an amino acid at the position 144 is substituted by a glutamic acid.
    • 本文描述了抗HBs​​单克隆抗体。 该抗体可以结合如下:(i)野生型HBsAg; (ii)至少一种选自第一突变体HBsAg和第二突变体HBsAg的突变体HBsAg; 和(iii)至少一种选自第三突变体HBsAg和第四突变体HBsAg的突变体HBsAg。 第一突变体HBsAg在位置120处具有突变。第二突变体HBsAg在141位具有突变。第三突变体HBsAg在位置118具有赖氨酸取代。第四突变体HBsAg在144位仅具有一个突变,氨基 位置144处的酸被谷氨酸取代。
    • 6. 发明授权
    • Process for analyzing annexin-V in urine, and application thereof
    • 分析尿液中膜联蛋白V的方法及其应用
    • US06830896B2
    • 2004-12-14
    • US10294558
    • 2002-11-15
    • Noboru KanekoRyuko MatsudaTadahiro Kajita
    • Noboru KanekoRyuko MatsudaTadahiro Kajita
    • G01N33543
    • G01N33/6893G01N2333/4718Y10S436/811
    • The present invention provides a process and regent for analyzing annexin-V, wherein the measurement of a concentration of annexin-V can be easily carried out without need for addition of chemicals for inhibiting the bonding of various proteins with calcium ion and for adjusting a specimen solution to the specimen at a measuring stage, and a process and medicine for diagnosing an internal organ disorder based on the analyzing process and regent. A urine is brought into contact with an anti-annexin-V monoclonal antibody to perform an antigen-antibody reaction of annexin-V in the urine with the anti-annexin-V monoclonal antibody, thereby forming an annexin-V antigen/anti-annexin-V monoclonal antibody complex, and the amount of the formed annexin-V antigen/anti-annexin-V monoclonal antibody complex is quantitatively measured. Thus, it is possible to carry out the measurement of the concentration of annexin-V in the urine, and it is possible to carry out the diagnosis of an internal organ disorder such as a disseminated intravascular coagulation syndrome, the diagnose of acute nephritis and the like by a analyzed value of concentration of annexin-V measured in the urine.
    • 本发明提供了用于分析膜联蛋白-V的方法和试剂,其中可以容易地进行膜联蛋白-V浓度的测量,而不需要添加用于抑制各种蛋白质与钙离子结合的化学物质和用于调节样品 在测量阶段对标本的溶液,以及基于分析过程和摄取的诊断内脏器官障碍的过程和药物。 使尿液与抗膜联蛋白-V单克隆抗体接触,进行尿中与膜联蛋白-V单克隆抗体的膜联蛋白-V的抗原 - 抗体反应,从而形成膜联蛋白-V抗原/抗 - 膜联蛋白 -V单克隆抗体复合物,并定量测定形成的膜联蛋白-V抗原/抗 - 膜联蛋白-V单克隆抗体复合物的量。 因此,可以进行尿中膜联蛋白-V浓度的测定,可以进行内部器官功能障碍的诊断,例如弥漫性血管内凝血综合征,急性肾炎诊断和 如通过在尿液中测量的膜联蛋白-V浓度的分析值。